Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRITON-PN: Nucresiran in hATTR-PN
NCT07223203Phase 3Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Lipid-based Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 22
01
Overview
A Phase 3 trial of nucresiran in hereditary transthyretin amyloidosis (hATTR), sponsored by Alnylam Pharmaceuticals. Started Feb 2026; status: recruiting.
02
Drugs
nucresiran
03
Conditions
hereditary transthyretin amyloidosis (hATTR)
Beyond the preview
Go deeper on NCT07223203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07223203.